help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

First published online on December 19, 2006
This version published online on February 23, 2007
Endocrine Reviews, doi:10.1210/er.2006-0029
Endocrine Reviews, doi:10.1210/er.2006-0029
Endocrine Reviews 0 (2007): 200600292-
Copyright © 2007 by The Endocrine Society
This Article
Right arrow Final Manuscript (PDF)
Right arrow All Versions of this Article:
28/2/151    most recent
Final Manuscript
Author Manuscript
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chavassieux, P.
Right arrow Articles by Delmas, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chavassieux, P.
Right arrow Articles by Delmas, P. D.

Insights into Material and Structural Basis of Bone Fragility from Diseases Associated with Fractures: How Determinants of the Biomechanical Properties of Bone Are Compromised by Disease

P. Chavassieux, E. Seeman, and P. D. Delmas*

Institut National de la Santé et de la Recherche Médicale Research Unit 831 and Université Claude Bernard-Lyon 1 (P.C., P.D.D.), 69372 Lyon Cedex 08, France; and Departments of Medicine and Endocrinology (E.S.), Austin Health, University of Melbourne, Heidelberg 3084, Melbourne, Australia

* To whom correspondence should be addressed. E-mail: delmas{at}lyon.inserm.fr.

Minimal trauma fractures in bone diseases are the result of bone fragility. Rather than considering bone fragility as being the result of a reduced amount of bone, we recognize that bone fragility is the result of changes in the material and structural properties of bone. A better understanding of the contribution of each component of the material composition and structure and how these interact to maintain whole bone strength is obtained by the study of metabolic bone diseases. Disorders of collagen (osteogenesis imperfecta and Paget's disease of bone), mineral content, composition and distribution (fluorosis and osteomalacia); diseases of high remodeling (postmenopausal osteoporosis, hyperparathyroidism, and hyperthyroidism) and low remodeling (osteopetrosis, pycnodysostosis); and other diseases (idiopathic male osteoporosis, corticosteroid-induced osteoporosis) produce abnormalities in the material composition and structure that lead to bone fragility. Observations in patients and in animal models provide insights on the biomechanical consequences of these illnesses and the nature of the qualities of bone that determine its strength.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
M. Visekruna, D. Wilson, and F. E. McKiernan
Severely Suppressed Bone Turnover and Atypical Skeletal Fragility
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2948 - 2952.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society